An observational study in Deformity, Defect, Congenital and Trauma, sponsored by Orthofix s.r.l.. Completed at 1 site in Germany. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Orthofix s.r.l. · Observational
Orthofix Srl put the JPS on the European market (2019) by the mean of a pre-market clinical evaluation made under the Medical Device Directive (MDD) requirements that were based on the analysis of the scientific literature of equivalent devices.
This study has been planned as part of the Orthofix Srl post-market active surveillance plan for the collection of data on both the clinical performance and the safety profile of the JPS in a representative population of Patients and users.
The rationale of the proposed study is to update and support the pre-market clinical evaluation of the JPS with real-word-evidence clinical data, in order to confirm the benefit/risk ratio of this medical device and to keep the CE mark under Medical Device Regulation (MDR) requirements.
One selected site that is experienced in the treatment of pediatric and adult patients with bone deformities and fractures, where the usage of JPS is already part of the normal clinical practice, will participate in this study. Investigator will provide data for a maximum of 40 JPS implant cases satisfying inclusion and exclusion criteria (predicted drop out rate is 10%) that will contribute for at least 30 cases treated by JPS (note that some patients may contribute for more than one JPS case, according to how many JPS implants were received).
For retrospective study cohort, who has previously had JPS implanted and follow-up assessment and JPS removal is done, the investigators shall purely collect clinical data from the medical record of the subjects, concerning the screening criteria, the surgery (MD application) and 4 following events: hospital discharge, first post-application control, bone consolidation assessment and device removal. Data from patients' observation are collected according to the site standard-of-care.
Patients, who are prospectively enrolled in the study and have undergone JPS implantation, will have follow-up assessments, as described on Table 10.2, or until patient withdrawal.
The patient data will be systematically collected by the investigator in eCRF. As per CIP, the subjects will not undergo additional visit nor non-invasive, invasive or burdensome procedures additional to those performed under the normal clinical practice.
980 studies on the registry are indexed under Congenital Abnormalities; 177 are open to participants now.
This study's enrollment of 30 is below the median of 153 across 446 observational studies indexed under Congenital Abnormalities.
Browse Congenital Abnormalities studies →Orthofix s.r.l. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will be conducted only on patients with a regular indication for JPS JuniOrtho Plating System as per IFU: the system is intended in pediatric (excluding newborns) and small stature adult patients. Pediatric patients include infants (greater than 1 month to 1 years of age), children (greater than 1 to 12 years of age), adolescents (greater than 12 to 18 years of age) and appropriate adults (where according to investigator assessment, the JPS plates fit the treated bone anatomy).
Inclusion Criteria: a patient will be eligible for inclusion in the study if:
Note: for the retrospective group of patients to whom all interventions and control visits were already done, a waiver of consent for retrospective data collection to be requested.
Exclusion Criteria: a Patient will be excluded from participation in the study if he/she:
This grup will include all patients with regular indication for JPS: system is intended in pediatric (excluding newborns) and small stature adult patients. Pediatric patients include infants (greater than 1 month to 1 years of age), children (greater than 1 to 12 years of age), adolescents (greater than 12 to 18 years of age) and appropriate adults (where according to investigator assessment, the JPS plates fit the treated bone anatomy).
Device: JuniOrtho™ Plating System™
The patient underwent surgery for the application of JPS for treatment of deformity or traumatic fracture.
Also known as: JPS
Percentage (%) of Subjects With at Least One Serious/Not Serious Adverse Event Certainly Related or Possibly Related to JPS (ADEs)
Percentage of subjects who experience at least one adverse event (serious or non-serious) that the investigator judges as certainly or possibly related to the JPS system (ADEs). This outcome is used to assess the safety profile of the JPS system.
Time frame: Up to 18 months from surgery (at device removal)
Percentage (%) of Subjects With at Least One Medica Device Deficiencies (MDDs)
Percentage of subjects who experienced at least one medical device deficiency (MDD) i.e., any inadequacy, malfunction, or nonconformance of the investigational device or its accessories, during the defined observation window. This outcome is used to asses the safety profile of the JPS system.
Time frame: Up to 18 months from surgery (at device removal)
Percentage (%) of Subjects That Reached a Satisfactory Bone Consolidation According to Investigator's Opinion
Percentage of subjects who achieved satisfactory bone consolidation, as judged by the investigator per protocol-defined criteria, up to the specified assessment time point. This outcome is used to asses the clinical performance of the JPS system.
Time frame: Up to 18 months from surgery (at device removal)
Percentage (%) of Subjects That Maintained Bone Correction Alignment According to Investigator's Opinion
Percentage of subjects who maintained bone correction alignment, as assessed by the investigator per protocol-defined criteria, up tp the specified follow-up time point. Note: This outcome is calculated only for the subgroup "JPS-Treated Patients for Deformity Correction.", that is the only patients that present a correction alignment. This outcome is used to asses the clinical performance of the JPS system.
Time frame: Up to 18 months from surgery (at device removal)
| Milestone | JPS Treated Patients |
|---|---|
| Started | 30 |
| Completed | 29 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of subjects who experience at least one adverse event (serious or non-serious) that the investigator judges as certainly or possibly related to the JPS system (ADEs). This outcome is used to assess the safety profile of the JPS system.
| percentage of subjects | JPS Treated Patients |
|---|---|
| Percentage (%) of Subjects With at Least One Serious/Not Serious Adverse Event Certainly Related or Possibly Related to JPS (ADEs) | 3.3 (0.1 to 17.4) |
Percentage of subjects who experienced at least one medical device deficiency (MDD) i.e., any inadequacy, malfunction, or nonconformance of the investigational device or its accessories, during the defined observation window. This outcome is used to asses the safety profile of the JPS system.
| percentage of subjects | JPS Treated Patients |
|---|---|
| Percentage (%) of Subjects With at Least One Medica Device Deficiencies (MDDs) | 70.0 (50.4 to 85.4) |
Percentage of subjects who achieved satisfactory bone consolidation, as judged by the investigator per protocol-defined criteria, up to the specified assessment time point. This outcome is used to asses the clinical performance of the JPS system.
| percentage of subjects | JPS Treated Patients |
|---|---|
| Percentage (%) of Subjects That Reached a Satisfactory Bone Consolidation According to Investigator's Opinion | 96.7 (82.6 to 99.9) |
Percentage of subjects who maintained bone correction alignment, as assessed by the investigator per protocol-defined criteria, up tp the specified follow-up time point. Note: This outcome is calculated only for the subgroup "JPS-Treated Patients for Deformity Correction.", that is the only patients that present a correction alignment. This outcome is used to asses the clinical performance of the JPS system.
| percentage of subjects | JPS-Treated Patients for Deformity Correction |
|---|---|
| Percentage (%) of Subjects That Maintained Bone Correction Alignment According to Investigator's Opinion | 96.3 (80.9 to 99.9) |
Collected over Adverse events were collected from treatment through the last available follow-up for each patient, with a maximum follow-up duration of up to 18 months, in accordance with site standard practice.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JPS Treated Patients | 0/30 (0%) | 2/30 (6.7%) | 4/30 (13.3%) |
| Event | JPS Treated Patients |
|---|---|
| Delayed union, nonunion, malunionMusculoskeletal and connective tissue disorders | 1/30 |
| Events caused by anesthesia and surgerySurgical and medical procedures | 1/30 |
| Loosening of the implant and loss of fixationInjury, poisoning and procedural complications | 1/30 |
| Event | JPS Treated Patients |
|---|---|
| Events caused by anesthesia and surgerySurgical and medical procedures | 4/30 |
| Age, Continuous(years) | JPS Treated Patients |
|---|---|
| Age at surgery | 19.9 ± 6.3 |
| Age at ICF signature | 21.1 ± 6.3 |
| Sex: Female, Male(Participants) | JPS Treated Patients |
|---|---|
| Female | 19 |
| Male | 11 |
| Race and Ethnicity Not Collected(Participants) | JPS Treated Patients |
|---|
| Region of Enrollment(Participants) | JPS Treated Patients |
|---|---|
| Germany | 30 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orthofix s.r.l.